Abstract Blood flukes or schistosomes are the causative agents of human schistosomiasis, one of the major neglected tropical diseases. Draft genome sequences have been reported for schistosomes, but functional genomics tools are needed to investigate the role and essentiality of the newly reported genes. Vector based RNA interference can contribute to functional genomics analysis for schistosomes. Using mRNA encoding reporter firefly luciferase as a model target, we compared the performance of a schistosome and a human promoter from the U6 gene in driving shRNA in human fibrosarcoma cells and in cultured schistosomes. Further, both a retroviral [Murine leukemia virus (MLV)] and plasmid (piggyBac, pXL-Bac II) vector were utilized. The schistosome U6 gene promoter was 270 bp in length, the human U6 gene promoter was 264 bp; they shared 41% identity. Following transduction of both HT1080 fibrosarcoma cells and schistosomules of Schistosoma mansoni with pseudotyped MLV virions, stronger knockdown of luciferase activity was seen with the virions encoding the human U6 promoter driven shRNA than the schistosome U6 promoter. A similar trend was seen after transfection of HT1080 cells and schistosomules with the pXL-Bac-II constructs-stronger knockdown of luciferase activity was seen with constructs encoding the human compared to schistosome U6 promoter. The findings indicate that a human U6 gene promoter drives stronger shRNA activity than its schistosome Raphaël Duvoisin and Mary A. Ayuk contributed equally.
Introduction
Vector-based RNAi approaches that lead to chromosomal integration of transgenes encoding cassettes expressing small interfering RNAs (siRNAs) can circumvent deficiencies with cytoplasmic RNAi approaches by providing long-term, continuous and/ or conditional gene silencing (ter Brake et al. 2006; Moore et al. 2010; Sliva and Schnierle 2010) . By contrast, delivery of dsRNAs/siRNAs from the exterior of the cell to the cytoplasm frequently delivers only transitory gene silencing, may be inaccessible to some developmental stages and/or tissues, can be expensive and, in addition, cytoplasmic dsRNAs may induce apoptosis and interferon signaling responses in some situations (Haasnoot et al. 2007; Sliva and Schnierle 2010; Handa et al. 2011) .
The schistosomes are considered the most important of the human helminth parasites in terms of the morbidity and mortality which they cause (Hotez et al. 2008; Han et al. 2009; Rollinson 2009; Gurarie et al. 2011) . In addition, Schistosoma haematobium is a cause of squamous cell carcinoma of the bladder and is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (Bouvard et al. 2009 ). Following the recent reports of the draft genome sequences of two of the major human schistosome species (Berriman et al. 2009 ; Schistosoma japonicum Genome Sequence and Functional Analysis Consortium 2009), efforts have increased towards harnessing the functional genomics approaches widely used in model species and human gene therapy for investigation of the importance and essentiality of these new schistosome genes (Stefanic et al. 2010; Collins et al. 2011) . Information obtained with these advances can be expected to guide development of new interventions for these major neglected tropical disease pathogens Han et al. 2009 ).
In relation to this interest in expanding functional genomics for schistosomes, it has been demonstrated that both pseudotyped murine leukemia virus (MLV) and the transposon piggyBac can transduce developmental stages of schistosomes, leading to chromosomal integration of retroviral transgenes and transgene reporter activity (Morales et al. 2007 ; Kines et al. 2008; Yang et al. 2010; Rinaldi et al. 2011 ). Moreover, vector-based RNAi approaches have been reported in schistosomes (e.g. Zhao et al. 2008) . The goal of the present investigation was to compare and contrast the performance of two U6 gene promoters, one from S. mansoni, the other from the human genome, in driving short hairpin RNAs in cultured schistosomes. There may be advantages to deploying a RNA polymerase (Pol III) promoter: the U6 promoter is known to competently and continuously transcribe small RNAs, is highly active in all or most cells and tissues where this has been examined (information on this aspect is not available for schistosomes, so it is not known whether Pol III is likewise widely active in cells of this flatworm), and its diminutive size fits within the limits on cargo size of the expression cassette (Paddison et al. 2002; Scherr and Eder 2007) . Defining active promoter elements for vector based RNAi in schistosomes can be expected to be worthwhile since studies of the human schistosomes are more problematic than established approaches with cultured mammalian cells or with more well studied model species such as Caenorhabditis elegans and Drosophila melanogaster. The present findings revealed the superior performance of a human U6 promoter when compared to an endogenous U6 promoter from S. mansoni in driving active shRNAs in cultured schistosomes.
Materials and methods

HT1080 fibrosarcoma cells expressing firefly luciferase
We employed a genetically modified HT1080 human fibrosarcoma cell line, that constitutively expresses luciferase, in these studies of short hairpin RNA (Ayuk et al. 2011) . In brief to generate a HT1080 cell line stably expressing luciferase, HT1080 cells (ATCC, Manassas, VA) were transduced with lentivirus virions (ViraPower Promoterless Lentiviral Gateway Expression System, Invitrogen) that includes a gene conferring resistance to blasticidin, and the firefly luciferase gene driven by the S. mansoni spliced leader RNA gene promoter (see Kines et al. 2006) in the presence of polybrene (Sigma). Blasticidin-resistant cells expressing luciferase were selected by culturing in the presence of blasticidin for 14 days. Stable cells were isolated, cryopreserved and/or expanded for use as target, luciferase expressing HT1080 cells for the vector based RNAi (below).
Schistosoma mansoni
Biomphalaria glabrata snails infected with the NMRI (Puerto Rican) strain of S. mansoni were supplied by Dr. Fred Lewis, Biomedical Research Institute, Rockville, MD, USA. Cercariae released from infected B. glabrata snails were mechanically transformed into schistosomules. In brief, cercariae were concentrated by centrifugation (425 g/10 min) and washed once with schistosomule wash medium (Dulbecco's modified Eagle's medium (DMEM) supplemented with 200 units/ml of penicillin, 200 lg/ml of streptomycin, 500 ng/ml of amphotericin B and 10 mM HEPES). Cercarial tails were sheared from the larvae by 20 passes through 22 gauge emulsifying needles after which schistosomule bodies were isolated from tails by Percoll gradient centrifugation (Lazdins et al. 1982) . Schistosomula were washed three times in schistosomule wash medium and cultured in Basch's medium (Basch 1981) at 37°C under 5% CO 2 in air for up to 14 days. Some cultures were supplemented with washed human erythrocytes, at a density of 1 ll of packed red cells per ml of medium ).
Construction of shRNA expression cassettes targeting firefly luciferase
The sequence of the human U6 small nuclear RNA gene (GenBank X07425) was used to design primers HsU6F and HsU6R (Table S1 ) and the primers employed to amplify upstream and part of the 5 0 -terminus of the U6 gene from genomic DNA from human white blood cells using a kit (ENZA, Omega Bio-tek, Doraville, GA). The amplicon was ligated into pCR4 TOPO (Invitrogen), the insert sequenced, the nucleotide sequence aligned with other human and schistosome U6 promoters, and this human U6 promoter sequence included in the shRNA expression cassette in the MLV pLNHXDD70 (generated by the removal of Drosophila heat shock 70 gene promoter from pLNHX using Xho I) (Suttiprapa, unpublished) and piggyBac (pXL-BacII) constructs assembled here (Fig. 1) . The S. mansoni U6 promoter has been described (Ayuk et al. 2011) . A two-step PCR approach was performed to construct the shRNA expression cassettes targeting firefly luciferase (Gou et al. 2003; Linford et al. 2009; Ayuk et al. 2011 ) that included either a human or a schistosome U6 promoter. The approach involved two rounds of PCR using one universal primer, specific for the promoter (human or schistosome) and two unique target sequences, the first oligonucleotide to add the sense strand of the shRNA, the second to add the loop region, anti-sense strand and terminal thymidines. For the hairpin sense strand, we included 21 residues, nucleotides 851-871, 5
0 -GTGCGCTGCTGGTGCCA ACCC-3 0 , of the firefly luciferase (cDNA) gene in pGL3 (Promega) because this site and target sequence length have been demonstrated in shRNA studies to lead to complete or near complete knockdown of luciferase activity in mammalian and insect cell lines (Gou et al. 2003; Wakiyama et al. 2005) . For a control shRNA, we constructed cassettes where the 21 target residues 851-871 of the luciferase gene were scrambled, as follows, 5 0 -ACCTACTGGGCAGGGAGCC GC-3 0 , using the same forward primer (above) and the reverse primers (Table S1 ). The final products were sized by agarose gel electrophoresis, eluted from gel, cleaved with Xho I for pLNHX and BamH I and Xho I for pXL-Bac II (Li et al. 2005) , and ligated into linearized retroviral or transposon vector plasmids. Figure 1 provides an illustration of the constructs, termed pLNHX_SmU6_shLuc (GenBank accession JN255692), pLNHX_HsU6_shLuc (JN255690), pLNHX_HsU6_ScramLuc (JN255691), pXL-BacII_SmU6-shLuc (HQ677838), pXL-BacII_SmU6-shScramLuc (HQ677839), pXL-BacII_HsU6-shLuc (JF298906), and pXL-BacII_HsU6-shScramLuc (JF298907). Sequences of oligonucleotide primers used in assembly of these shRNA expression cassettes are provided in Table S1 .
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Production of pseudotyped retroviral virions
Plasmid constructs, prepared with a maxiprep kit (5 Prime, Gaithersburg, MD), were employed to produce the virions as described (Kines et al. 2010; Rinaldi et al. 2011) . In brief, GP2-293 cells were co-transfected with the MLV encoding plasmid ( Fig. 1 ) along with pVSVG, which encodes vesicular stomatitis virus glycoprotein (the pseudotyping envelope) using liposomes (Lipofectamine 2000, Invitrogen). Culture supernatants were collected 48 h later, filtered through 0.45 lm pore size membranes, the filtrate incubated with DNAse I (New England Biolabs, Ipswich, MA) to remove contaminating plasmids, and virions in culture supernatants recovered by centrifugation (Sorvall SS34 rotor, 50,000g, 90 min, 4°C). Pelleted virions were resuspended in schistosomule wash medium (above), virion titers estimated using quantitative PCR , and aliquots of virions stored at -80°C until needed. pLNHXDD70 was employed to produce control virions without shRNA encoding cassettes.
Messenger RNA encoding firefly luciferase
For preparation of firefly luciferase mRNAs (mLuc), in vitro transcriptions of capped RNAs from template PCR products from the luciferase gene in pGL3-Basic (Promega) were accomplished using the mMessage mMachine T7 Ultra kit (Ambion) (Correnti and Pearce 2004) . mLuc was precipitated with one volume of 5 M ammonium acetate and 2.5 volumes of 95% ethanol after which the precipitate was dissolved in water and concentration and purity determined using a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Transduction of HT1080 cells
Luciferase expressing HT1080 cells were plated at a density of 2 to 5 9 10 5 in 6-well (35 mm) plates to achieve 30-50% confluence the following day. For transduction with retroviral virions, pLNHX_ HsU6_shLuc or pLNHX_HsU6_Scram control virions (6.5 9 10 8 virions) were added to the cells which were then cultured for 18 h in 2 ml of DMEM supplemented with 10% FBS, 100 units/ml of penicillin, 100 lg/ml of streptomycin and 8 lg/ml polybrene. Culture media were changed the following day. The transduced cells were harvested at 96 h after addition of virions. For some experiments, transduced HT1080 cells were subjected to selection on G418 at 500 lg/ml for 10 days, since the retroviral encodes the neomycin resistance gene (Fig. 1) , with changes of culture media every second day. After harvesting, cells were counted and lysed in CCLR buffer (Promega) in order to determine levels of luciferase activity (below).
In like fashion, HT1080 cells at *90% confluence were transfected with 4 lg of plasmid pXL-BacII_ SmU6-shLuc, pXL-BacII_SmU6-shScramLuc, pXLBacII_HsU6-shLuc or pXL-BacII_HsU6-shScramLuc using Lipofectamine 2000. A control group of cells not transfected with plasmids but exposed to the liposomes was included (mock). The following day, cells were washed with 19 PBS, and then cultured for 96 h in DMEM supplemented with 10% FBS, 100 units/ml of penicillin, 100 lg/ml of streptomycin. Cells were counted and lysed, as above.
Transduction of schistosomules
For transduction of schistosomes, virions-at titers ranging from 2.6 9 10 9 to 1.5 9 10 10 per treatment well-were added to cultures of 7 day old schistosomules, 10 3 -10 4 schistosomules per well (24-well plates; Corning) in one ml schistosomule media containing 8 lg/ml polybrene. Media were changed at 18 h after addition of virions, after which schistosomules were maintained in culture for 3 days. At this point these schistosomules were transfected with mRNA encoding firefly luciferase. Three hours after electroporation the parasites were harvested for luciferase activity assays. In some experiments, the schistosomules were exposed to the virus by centrifugation (800g, 60 min, 21°C) in the presence of polybrene.
Schistosomules were transfected with pXL-Bac II constructs by square wave electroporation; the worms were transferred to cuvettes (4 mm gap, BTX, San Diego, CA, USA) containing media supplemented with 20 lg of plasmid (pXL-BacII_ SmU6-shLuc or pXL-BacII_SmU6-shScramLuc or pXL-BacII_ HsU6-shLuc or pXL-BacII_HsU6-shScramLuc) and then subjected to a square wave pulse of 125 V of 20 ms duration, using a BTX ElectroSquarePoratorTM ECM830, as described (Kines et al. 2010) . Transfected worms were transferred to pre-warmed Basch's medium and maintained in culture for 48 h. mRNA encoding firefly luciferase was introduced into the cultured worms by electroporation (using the same conditions as for the plasmids). After electroporation, the schistosomules were maintained in culture for 3 h and then washed free of culture media, and wet pellets of worms snap frozen and stored at -80°C. [It is pertinent to note that exposing worms twice to electroporation may be deleterious, and reflected in inconsistent outcomes in the replicates (Ayuk et al. 2011) ].
Luciferase activity assay HT1080 cells and schistosomules were harvested, lysed, clarified supernatant (after centrifugation of lysates, 10,000g, 10 min 4°C), analyzed for luciferase activity. Aliquots of 100 ll of lysate were injected into100 ll luciferin (Promega) at 25°C, mixed, and the relative light units (RLUs) determined in a tube luminometer (Sirius, Berthold, Pforzheim, Germany) 10 s later (Correnti and Pearce 2004) . Replicate samples were measured, with results presented as the average of the readings of relative light units (RLU) per second per lg of soluble HT1080 or schistosome protein. Recombinant firefly luciferase (Promega) was included as a positive control in order to verify that the luciferin substrate and luminometer were functioning in a normal, expected fashion. Protein concentration of soluble fractions of transduced HT1080 cell and schistosome extracts were determined using the bicinchoninic acid assay (BCA kit, Pierce, Rockford, IL).
Results
U6 promoters diverge between schistosomes and humans
Whereas it was clear from a recent study that a U6 promoter from S. mansoni drove shRNA expression (Ayuk et al. 2011 ), here we compared the performance of a human U6 promoter with a schistosome orthologue since the human U6 promoter is used widely in shRNA studies (Makinen et al. 2006; Roelz et al. 2010) , including its inclusion as the promoter in the commercial vector pENTR/U6 from Invitrogen. Several U6 genes from the human genome are active although it appears that the promoter termed U6-1 is the widely utilized variant (Kunkel and Pederson 1988; Domitrovich and Kunkel 2003 ) (GenBank X07425). We aligned the X07425 sequence, the human U6 promoter from pENTR/U6 (here termed Invitrogen_U6), and GenBank JN255693, a variant of the human U6 promoter we cloned and sequenced from the blood donated by a co-author of this report, and a S. mansoni U6 gene promoter (HQ540317) (alignment not shown but available from corresponding author). The schistosome U6 gene promoter was 270 bp in length, the human U6 gene promoter was 264 bp, and they shared 41% identity. By contrast, the three human orthologues aligned were nearly identical; X07425 differed from JN255693 and Invitrogen_U6 by the inclusion of an additional residue, a thymidine (T) at position-98. This T occurred outside conserved Pol III binding domains, SPH, OCT, PSE and TATA, which were identical in the three human sequences. However, clear differences were apparent in all four domains between the schistosome (HQ540317) and human U6 promoters (Ayuk et al. 2011) . The human U6 gene promoter in GenBank JN255693 was included as the promoter in shRNA expression cassettes constructed here (Fig. 1) .
Human U6 promoter drives shRNA activity in schistosomes At the outset, we examined the human U6 promoter in the context of transduction of schistosomules by pLNHX based virions. Human fibrosarcoma HT1080 cells, stably expressing luciferase, and 7 day old schistosomules were transduced with retroviruses encoding the shRNA targeting firefly luciferase or a scrambled sequence (control). As shown in Fig. 2 , in both the HT1080 cells (panel A) and the schistosomes (panel B), which had been transfected with firefly luciferase encoding mRNA (mLuc), substantial knockdown of luciferase was apparent in the target HT1080 (47% knockdown) and schistosome parasites (81%) (Fig. 2 , panel A (HT1080 cells), and panel B (schistosomules) when the effect of the pLNHX_HsU6-shLuc and pLNHX_HsU6_Scram virions was compared. Similar findings were seen when transduced HT1080 cells were selected on geneticin/G418 for 10 days (49%) ( Figure S1, panel A) . Also, similar results were seen with schistosomules at 10 days after transduction by virions (60%) and in schistosomules exposed to the virus by centrifugation (85%) ( Figure S1 , panels B and C, respectively). Following retroviral transduction, human U6 drives stronger shRNA than schistosome U6 in schistosomules Having determined above that the heterologous human U6 promoter was active in shRNA cassettes in schistosomes, we next compared the performance of the schistosome and human U6 promoters in schistosomes. Groups of schistosomules were transduced with pLNHX_HsU6-shLuc, pLNHX_SmU6-shLuc virions, or control pLNHXDD70 virions. An additional control group, the mock transduction group exposed only to polybrene, was included. In the experiment presented in Fig. 3 , a knockdown of 38% luciferase activity was observed in schistosomules transduced with pLNHX_HsU6-shLuc virions compared to both mock and pLNHXDD70 control groups. By contrast, no knockdown was observed in worms transduced with the pLNHX_SmU6-shLuc virions. This same trend was observed in two replicates of this experiment (not shown). Thus, the human U6 promoter drove stronger shRNA activity than its schistosome orthologue in S. mansoni. Indeed, the schistosome promoter was barely or not active under these conditions. Human U6 promoter drove stronger shRNA activity than schistosome U6 promoter after delivery of transgenes in a transposon plasmid In addition to MLV retroviral based transgenesis of schistosomes and HT1080 cells to compare the human and schistosome U6 promoters, we carried out parallel studies using the piggyBac transposon plasmid pXLBac II (Fig. 1) . As above, we targeted HT1080 cells expressing luciferase and schistosomules transfected exogenously with luciferase encoding mRNA (mLuc). First, in each target type, the promoter driving the shRNA targeting luciferase produced a strong knockdown of luciferase in contrast to the control constructs targeting the scrambled sequence (Fig. 4 , panels A and B). In both HT1080 and in schistosomules, the human U6 promoter delivered greater knockdown of luciferase activity than the schistosome U6 promoter; 88% versus 75% in HT1080, 80% versus 35% in schistosomules. By contrast, similar levels of luciferase activity were evident in cells (or schistosomes) transfected with the control constructs, pXL-BacII_ SmU6-shScramLuc (SScram) or pXL-BacII_HsU6-shScramLuc (HScram). Similar findings were seen on each of two occasions these assays were performed ( Figure S2 ). [Luciferase levels in the mock i.e. no shRNA control were somewhat higher than in cells (or schistosomules) transfected with the shRNA control plasmids, a phenomenon we have seen and discussed previously (Ayuk et al. 2011) ].
Discussion
Deployment of shRNA for RNA interference represents a new strategy for functional genomics analyses of schistosomes and the human helminth parasites at large, which are major neglected disease pathogens. Whereas this is an emerging area, three recent reports have shown that both Pol II and Pol III promoters drive short hairpins in Schistosoma japonicum and S. mansoni that can silence target genes (Zhao et al. 2008; Tchoubrieva et al. 2010; Ayuk et al. 2011 ). The findings revealed that endogenous genes-mago nashi in S. japonicum and cathepsin B in S. mansoni, as well as reporter firefly luciferase, can be silenced following transfection of the schistosomes with transgene cassettes encoding cognate hairpin RNAs. Furthermore, endogenous-S. mansoni actin (Tchoubrieva et al. 2010) and S. mansoni U6 (Ayuk et al. 2011 )-and a heterologous promoter-human H1 (Zhao et al. 2008 )-were shown to be active.
Here endo-and exogenous orthologues of U6 gene promoters were examined for performance in shRNA expression cassettes in S. mansoni. Promoters from the genomes of both S. mansoni and Homo sapiens were tested as components of the shRNA cassettes. The genomes of both humans and schistosomes include numerous copies of the U6 small nuclear RNA gene: there are at least nine copies of the human U6 gene, five of which are active (Domitrovich and Kunkel 2003) , and nine to 55 copies of the S. mansoni orthologue (Copeland et al. 2009 ). The copy of the human U6 gene promoter tested here appeared to be identical or close to identical to U6-1 (Domitrovich and Kunkel 2003) , a well-characterized copy that efficiently drives shRNAs in human cells and cells from non-congruent species (Boden et al. 2003; Roelz et al. 2010) . We employed both pseudotyped retrovirus (MLV) and piggyBac based vectors, both known to integrate transgenes into chromosomes of this platyhelminth parasite (Morales et al. 2007; Kines et al. 2008) . Notably, the findings revealed that the human U6 promoter displayed superior performance to the schistosome U6 orthologue: in both the retroviral and donor transposon contexts, the human U6 promoter drove stronger knockdown of firefly luciferase in a human fibrosarcoma cell line and in cultured schistosomes.
The promoters were of similar length, 264 nt for human U6 and 270 nt for S. mansoni, but were only 41% identical. The binding motifs for Pol III in the human U6 promoter have been characterized (Domitrovich and Kunkel 2003) . They include an enhancer region, also termed the distal sequence element (DSE). The DSE consists of an octamer motif (OCT) and a Sph I post-octamer homology (SPH) element. In addition, a core region comprises a proximal sequence element (PSE) and a TATA-like element (Dahlberg and Schenborn 1988; Sturm et al. 1988; Schaub et al. 1999; Myslinski et al. 2001 ). Based on greater or lesser identity to the human and mouse motifs, previously we identified these prospective motifs of the enhancer and core regions in the 270 bp upstream of a schistosome U6 gene (Ayuk et al. 2011) . It is feasible that clear differences in sequence in the PSE and other domains-for example, TATGATA versus TATATA for the TATA motif; ATTACTAT versus ATTTG-CAT for the OCT motif in the schistosome and human promoters, respectively (Ayuk et al. 2011 )-were reflected in the differential activity of the human and schistosome U6 gene promoters. However, confirmation of the influence of these motif differences of the schistosome and human U6 promoters in schistosomes awaits further investigation. In addition, other copies of the S. mansoni U6 promoter may exhibit sequence differences that drive stronger shRNA expression, as has been demonstrated among the human U6 gene orthologues (Domitrovich and Kunkel 2003) .
The present results extend earlier findings wherein it was demonstrated the schistosome U6 promoter drove shRNA in both targets-HT1080 fibrosarcoma cells and blood stage schistosomes. However, based on these findings, we recommend deployment of the human U6 promoter rather than the schistosome promoter in future shRNA investigations. Zhao et al. (2008) demonstrated the activity of the human H1 gene promoter for shRNAs in S. japonicum. Makinen et al. (2006) demonstrated that the human U6 was more efficient than the H1 promoter in silencing reporters in both human (293T) and murine (c166-GFP) cell lines, leading to 80% knockdown of the transcript encoding green fluorescent protein. Similar trends were apparent in vivo, in mouse brains.
[H1 RNA is the RNA component of the human nuclear RNase P; the H1 promoter, which like that of U6 is a type 3 RNA polymerase III promoter, is unusually compact (Myslinski et al. 2001 ).] Moreover, shRNA expression from the human U6 promoter resulted in a four-fold increase in knockdown efficiency compared to expression from the mouse U6 promoter in human and in mouse cell lines (Roelz et al. 2010) . Accordingly, the human U6 promoter appears in general to drive strong shRNA based knockdown; the present findings demonstrated that this also occurs in schistosomes. In less well studied helminth parasites (Rinaldi et al. 2008) , it is reasonable to expect the human U6 gene would also be serviceable for shRNA investigations. Indeed, deploying the human U6 promoter could provide an initial way forward with functional studies in less well studied species, for example the helminth parasites of humanity at large, until endogenous (congruent) U6 genes could be isolated and tested. In relation to S. mansoni or other schistosome species, deploying the human U6 gene promoter should allow studies to progress while other copies of the schistosome U6 gene can be investigated.
To conclude, these findings indicated superior performance of a human U6 promoter over a schistosome U6 promoter in cassettes driving shRNAs to silence reporter genes in schistosomes, at least in blood stage schistosomules of S. mansoni. We are interested to establish long-term, stable and transgenerational RNAi to facilitate investigation of the essentiality of schistosome genes which could, in turn, be targeted in new approaches for treatment and control of schistosomiasis. The human U6 gene promoter clearly represents a potentially valuable transgene element for shRNA studies in schistosomes. High throughput, vector-based RNAi analysis can be expected to advance functional genomics for schistosomes in assisting the discovery of novel targetable genes (Stefanic et al. 2010) .
